PsyCan Welcomes Bill C-286, Thomas’ Bill, to Create a Clearer Regulated Pathway for Medical Psilocybin Access (opens original article in a new tab)

PsyCan supports Bill C-286, which seeks to establish a regulated pathway for medical psilocybin access in Canada by modifying drug classification and streamlining approval processes.

• PsyCan welcomes Bill C-286 to create a regulated pathway for medical psilocybin access in Canada.
• The bill aims to remove psilocybin and psilocin from restricted-drug status and expedite Health Canada's review process.
• Thomas Hartle's story highlights the need for a clearer system after his experience with bureaucratic delays in accessing psilocybin therapy.